Reata launched a two-part study of RTA 408 in individuals with FA, ages 16-40 years (the MOXIe study). The first part of this study uses a dose escalation design with cohorts of eight patients enrolled per dose group. So far, four dose groups for a total of 32 patients have been enrolled.
A fifth dose group will open for enrollment in January 2016, and additional dose escalation groups may also be opened during 2016. After dose escalation in part one of MOXIe is complete, which is expected to occur in the second half of 2016, Reata expects to initiate the second part of the study, focused on efficacy.
Thank you to everyone in the FA community who is participating in the study. Additional international sites are being added in Australia and Europe. For more information about this trial and sites participating visit, www.curefa.org/active-clinical-trials